Health Trials

Combination of Zanubrutinib, Rituximab and Venetoclax in Patients With Previously Untreated Follicular Lymphoma

ConditionsAnn Arbor Stage II Follicular LymphomaGrade 1 Follicular LymphomaAnn Arbor Stage III Follicular LymphomaAnn Arbor Stage IV Follicular LymphomaGrade 2 Follicular LymphomaGrade 3a Follicular Lymphoma
Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18+
SponsorChinese PLA General Hospital

About this trial

This is a single center, open label, single arm phase II clinical trial. The objective of this study is to assess the feasibility and efficacy of zanubrutinib combined with venetoclax and Rituximab in patients with previously untreated follicular lymphoma (FL) .

Eligibility criteria

Qualifiers

A diagnosis of follicular lymphoma (grades 1, 2, or 3a), untreated.

Stage II, III, or IV disease.

Able and willing to provide written informed consent and to comply with the study protocol.

at least one measurable disease.

Disqualifiers

Known active central nervous system lymphoma or leptomeningeal disease

Follicular lymphoma with evidence of diffuse large B-cell transformation

Grade 3b follicular lymphoma

Any prior history of other malignancy besides follicular lymphoma

Trial design

Treatments tested in this trial

  • Zanubrutinib
  • Rituximab
  • Venetoclax

Treatment groups

30 Participants
are divided into 1 treatment group

Sponsors and collaborators

Chinese PLA General Hospital

Lead sponsor

Source ClinicalTrials.gov